Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study

@article{Adamo2008PegylatedLD,
  title={Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study},
  author={Vincenzo Adamo and Vito Lorusso and Rosalba Rossello and Barbara Adamo and Giuseppa Ferraro and Domenica Lorusso and Giovanni Condemi and Domenico Priolo and Liberato Di Lullo and Amelia Paglia and Salvatore Pisconti and Giovanni Scambia and Gabriella Ferrandina},
  journal={British Journal of Cancer},
  year={2008},
  volume={98},
  pages={1916 - 1921}
}
This multicentre phase II study was aimed at investigating the activity and safety of pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) as front-line therapy in a large series of chemotherapy-naïve recurrent/metastatic breast cancer patients. From June 2003 to December 2006, a total of 71 recurrent/metastatic breast cancer patients were enrolled… CONTINUE READING